CA3137271A1 - Methods of treating sjogren's syndrome using a bruton's tyrosine kinase inhibitor - Google Patents
Methods of treating sjogren's syndrome using a bruton's tyrosine kinase inhibitor Download PDFInfo
- Publication number
- CA3137271A1 CA3137271A1 CA3137271A CA3137271A CA3137271A1 CA 3137271 A1 CA3137271 A1 CA 3137271A1 CA 3137271 A CA3137271 A CA 3137271A CA 3137271 A CA3137271 A CA 3137271A CA 3137271 A1 CA3137271 A1 CA 3137271A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962851994P | 2019-05-23 | 2019-05-23 | |
| US62/851,994 | 2019-05-23 | ||
| PCT/IB2020/054754 WO2020234781A1 (en) | 2019-05-23 | 2020-05-20 | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3137271A1 true CA3137271A1 (en) | 2020-11-26 |
Family
ID=70918750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3137271A Pending CA3137271A1 (en) | 2019-05-23 | 2020-05-20 | Methods of treating sjogren's syndrome using a bruton's tyrosine kinase inhibitor |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US12383556B2 (https=) |
| EP (2) | EP3972603B1 (https=) |
| JP (2) | JP7765970B2 (https=) |
| KR (1) | KR20220011652A (https=) |
| CN (1) | CN113811301A (https=) |
| AU (2) | AU2020278236C1 (https=) |
| BR (1) | BR112021023110A2 (https=) |
| CA (1) | CA3137271A1 (https=) |
| CL (1) | CL2021003034A1 (https=) |
| DK (1) | DK3972603T3 (https=) |
| ES (1) | ES3004516T3 (https=) |
| FI (1) | FI3972603T3 (https=) |
| HR (1) | HRP20241584T1 (https=) |
| HU (1) | HUE069020T2 (https=) |
| IL (1) | IL287745B2 (https=) |
| LT (1) | LT3972603T (https=) |
| MX (1) | MX2021014161A (https=) |
| PL (1) | PL3972603T3 (https=) |
| PT (1) | PT3972603T (https=) |
| RS (1) | RS66195B1 (https=) |
| SI (1) | SI3972603T1 (https=) |
| TW (1) | TWI857060B (https=) |
| WO (1) | WO2020234781A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021023110A2 (pt) | 2019-05-23 | 2022-04-12 | Novartis Ag | Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton |
| MX2023008671A (es) * | 2021-01-26 | 2023-09-25 | Novartis Ag | Composicion farmaceutica. |
| CN116782888A (zh) * | 2021-01-26 | 2023-09-19 | 诺华股份有限公司 | 药物组合物 |
| JP7564347B2 (ja) | 2021-09-03 | 2024-10-08 | ノバルティス アーゲー | 多発性硬化症を治療するためのｌｏｕ０６４ |
| US20250032488A1 (en) | 2021-12-14 | 2025-01-30 | Novartis Ag | Methods of treatment using lou064 |
| TW202342048A (zh) | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | 使用ｌｏｕ０６４治療化膿性汗腺炎之方法 |
| KR102875105B1 (ko) | 2023-04-03 | 2025-10-21 | 주식회사 사이알바이오 | 재조합 세마포린 4d 차단항체를 유효성분으로 포함하는 쇼그렌 증후군 예방 또는 치료용 약학 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ532310A (en) | 2001-10-05 | 2007-02-23 | Combinatorx Inc | Combinations comprising a tetra-substituted pyrimidopyrimidine and a corticosteroid for the treatment of immunoinflammatory disorders |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| LT3390390T (lt) | 2015-12-16 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui |
| US10570118B2 (en) | 2016-01-13 | 2020-02-25 | Boehringer Ingelheim International Gmbh | Isoquinolones as BTK inhibitors |
| US10874741B2 (en) | 2017-08-28 | 2020-12-29 | Spectrix Therapeutics, LLC | Compound to treat Sjogren's syndrome |
| KR20200074993A (ko) | 2017-11-03 | 2020-06-25 | 노파르티스 아게 | 쇼그렌 증후군 치료에 사용하기 위한 항-cd40 항체 |
| TWI694995B (zh) * | 2017-11-06 | 2020-06-01 | 美商美國禮來大藥廠 | Btk抑制劑化合物 |
| BR112021023110A2 (pt) | 2019-05-23 | 2022-04-12 | Novartis Ag | Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton |
-
2020
- 2020-05-20 BR BR112021023110A patent/BR112021023110A2/pt unknown
- 2020-05-20 WO PCT/IB2020/054754 patent/WO2020234781A1/en not_active Ceased
- 2020-05-20 HR HRP20241584TT patent/HRP20241584T1/hr unknown
- 2020-05-20 CN CN202080032174.XA patent/CN113811301A/zh active Pending
- 2020-05-20 RS RS20241280A patent/RS66195B1/sr unknown
- 2020-05-20 US US17/612,737 patent/US12383556B2/en active Active
- 2020-05-20 SI SI202030536T patent/SI3972603T1/sl unknown
- 2020-05-20 CA CA3137271A patent/CA3137271A1/en active Pending
- 2020-05-20 FI FIEP20729203.8T patent/FI3972603T3/fi active
- 2020-05-20 HU HUE20729203A patent/HUE069020T2/hu unknown
- 2020-05-20 DK DK20729203.8T patent/DK3972603T3/da active
- 2020-05-20 LT LTEPPCT/IB2020/054754T patent/LT3972603T/lt unknown
- 2020-05-20 EP EP20729203.8A patent/EP3972603B1/en active Active
- 2020-05-20 ES ES20729203T patent/ES3004516T3/es active Active
- 2020-05-20 MX MX2021014161A patent/MX2021014161A/es unknown
- 2020-05-20 JP JP2021568431A patent/JP7765970B2/ja active Active
- 2020-05-20 PT PT207292038T patent/PT3972603T/pt unknown
- 2020-05-20 AU AU2020278236A patent/AU2020278236C1/en active Active
- 2020-05-20 IL IL287745A patent/IL287745B2/en unknown
- 2020-05-20 PL PL20729203.8T patent/PL3972603T3/pl unknown
- 2020-05-20 KR KR1020217039591A patent/KR20220011652A/ko active Pending
- 2020-05-20 EP EP24191253.4A patent/EP4442321A3/en active Pending
- 2020-05-21 TW TW109116855A patent/TWI857060B/zh active
-
2021
- 2021-11-17 CL CL2021003034A patent/CL2021003034A1/es unknown
-
2025
- 2025-07-14 JP JP2025118412A patent/JP2025165957A/ja active Pending
- 2025-07-14 US US19/268,023 patent/US20250339428A1/en active Pending
- 2025-11-06 AU AU2025263830A patent/AU2025263830A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250339428A1 (en) | Methods of treating sjogren's syndrome using a bruton's tyrosine kinase inhibitor | |
| EP3972604B1 (en) | A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria | |
| US20250090538A1 (en) | Tlr7/8-antagonist for treating sjögren's syndrome or mixed connective tissue disease | |
| HK40110203A (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| RU2824354C2 (ru) | Способы лечения синдрома шегрена с применением ингибитора тирозинкиназы брутона | |
| HK40061327A (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| HK40061327B (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| WO2020234780A1 (en) | Methods of treating asthma using a bruton's tyrosine kinase inhibitor | |
| HK40126655A (en) | Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor | |
| HK40061328A (en) | A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria | |
| HK40061328B (en) | A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240416 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241225 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241225 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241225 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250523 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250916 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251121 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251121 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251121 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260421 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260421 |